计算溶液所需的质量、体积或浓度。
活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
---|
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
A127419-5mg |
5mg |
现货 ![]() |
| |
A127419-25mg |
25mg |
现货 ![]() |
| |
A127419-100mg |
100mg |
现货 ![]() |
|
英文别名 | 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide | NCGC00253562-01 | HY-50907 | 4-{4-[(4'-chloro[biphenyl]-2-yl)methyl]piperazin-1-yl}-N-[(4-{[(2R)-4-(di |
---|---|
规格或纯度 | Moligand™, ≥97% |
英文名称 | ABT-737 |
生化机理 | ABT-737是一种泛Bcl-2抑制剂,对急性淋巴细胞白血病(ALL)细胞系和异种移植具有广泛的单药活性。Bcl-2家族蛋白在癌症中的表达增加与化疗耐药性有关,抑制Bcl-2或Bcl-XL的过度表达有可能诱导癌细胞凋亡,同时对正常细胞的影响极小。触发 Bax/Bak 介导的细胞凋亡(对 Bcl-xL、Bcl-2 和 Bcl-w 介导的细胞凋亡的 EC 50 值分别为 79、30 和 198 nM)。在体内具有抗肿瘤作用。 |
储存温度 | -20°C储存 |
运输条件 | 超低温冰袋运输 |
作用类型 | 拮抗剂 |
作用机制 | 类 Bcl-2 1 拮抗剂;类 Bcl-2 2 拮抗剂 |
备注 | 需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
产品介绍 |
ABT-737是 Bcl-xL, Bcl-2 和 Bcl-w抑制剂,EC50分别为78.7 nM,30.3 nM和197.8 nM。对Mcl-1, Bcl-B 和 Bfl-1无抑制性。A selective inhibitor of Bcl-2 ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. |
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
---|
分子类型 | 小分子 |
---|---|
IUPAC Name | 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide |
INCHI | InChI=1S/C42H45ClN6O5S2/c1-46(2)23-22-35(30-55-37-9-4-3-5-10-37)44-40-21-20-38(28-41(40)49(51)52)56(53,54)45-42(50)32-14-18-36(19-15-32)48-26-24-47(25-27-48)29-33-8-6-7-11-39(33)31-12-16-34(43)17-13-31/h3-21,28,35,44H,22-27,29-30H2,1-2H3,(H,45,50)/t35-/m1/s1 |
InChi Key | HPLNQCPCUACXLM-PGUFJCEWSA-N |
Canonical SMILES | CN(C)CCC(CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-] |
Isomeric SMILES | CN(C)CC[C@H](CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-] |
分子量 | 813.43 |
Reaxy-Rn | 20196785 |
Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=20196785&ln= |
溶解性 | DMSO ≥160mg/mL Water <1.2mg/mL Ethanol <1.2mg/mL |
---|---|
密度 | 1.4 |
折光率 | 1.7 |
熔点 | 148-151°C |
分子量 | 813.400 g/mol |
XLogP3 | 9.000 |
氢键供体数Hydrogen Bond Donor Count | 2 |
氢键受体数Hydrogen Bond Acceptor Count | 10 |
可旋转键计数Rotatable Bond Count | 15 |
精确质量Exact Mass | 812.258 Da |
单同位素质量Monoisotopic Mass | 812.258 Da |
拓扑极表面积Topological Polar Surface Area | 164.000 Ų |
重原子数Heavy Atom Count | 56 |
形式电荷Formal Charge | 0 |
复杂度Complexity | 1320.000 |
同位素原子数Isotope Atom Count | 0 |
定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
所有立体化学键的总数The total count of all stereochemical bonds | 0 |
共价键合单元计数Covalently-Bonded Unit Count | 1 |
Reaxy-Rn | 20196785 |
---|---|
Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=20196785&ln= |
Purity(HPLC) | 97-100(%) |
---|---|
Appearance(A127419) | Faint Yellow to Yellow Crystals or Flakes |
NMR spectrum | Conforms to Structure |
1. Yun Zhou, Ke Li, Fan Li, Shuang Han, Yang Wang, Xueping Li, Yonghua Zhan. (2019) Doxorubicin and ABT-199 Coencapsulated Nanocarriers for Targeted Delivery and Synergistic Treatment against Hepatocellular Carcinoma. Journal of Nanomaterials, 2019 (5274598). [10.1155/2019/5274598] |
1. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace Jr AJ. (2000) An informatics approach identifying markers of chemosensitivity in human cancer cell lines.. Cancer Res, 60 (21): (6101-10). [PMID:11085534] [10.1021/op500134e] |
2. Green DR, Evan GI. (2002) A matter of life and death.. Cancer Cell, 1 (1): (19-30). [PMID:12086884] [10.1021/op500134e] |
3. Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A. (2007) The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.. Clin Cancer Res, 13 (23): (7191-8). [PMID:18056200] [10.1021/op500134e] |
4. Bruncko M, Oost TK, Belli BA, Ding H, Joseph MK, Kunzer A, Martineau D, McClellan WJ, Mitten M, Ng SC et al.. (2007) Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.. J Med Chem, 50 (4): (641-62). [PMID:17256834] [10.1021/op500134e] |
5. Jain HV, Meyer-Hermann M. (2011) The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas.. Cancer Res, 71 (3): (705-15). [PMID:21169413] [10.1021/op500134e] |
6. Tian BP, Xia LX, Bao ZQ, Zhang H, Xu ZW, Mao YY, Cao C, Che LQ, Liu JK, Li W et al.. (2017) Bcl-2 inhibitors reduce steroid-insensitive airway inflammation.. J Allergy Clin Immunol, 140 (2): (418-430). [PMID:28043871] [10.1021/op500134e] |
7. Lheureux S, N'Diaye M, Blanc-Fournier C, Dugué AE, Clarisse B, Dutoit S, Giffard F, Abeilard E, Briand M, Labiche A et al.. (2015) Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.. Int J Cancer, 136 (5): (E340-50). [PMID:25066666] [10.1021/op500134e] |
8. Yun Zhou, Ke Li, Fan Li, Shuang Han, Yang Wang, Xueping Li, Yonghua Zhan. (2019) Doxorubicin and ABT-199 Coencapsulated Nanocarriers for Targeted Delivery and Synergistic Treatment against Hepatocellular Carcinoma. Journal of Nanomaterials, 2019 (5274598). [10.1155/2019/5274598] |